LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients

Fortis Malar Hospitals posts Q1 FY2023 consolidated loss at Rs. 2.96 Cr

The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.

Jubilant Pharmova posts Q1FY23 consolidated PAT at Rs. 47.04 Cr

The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.

PIB: Quality control of Ayush drugs

PIB: Budget allocation and utilization of funds under National Ayush Mission

The total budget of Rs. 3119.46 crores has been allocated/ released as a central share to States/UTs since the inception of the scheme and they have reported an expenditure of Rs. 2290.20 crores.

PIB: Development of Ayush entrepreneurship

Ministry of Ayush signed a MoU with Ministry of Micro, Small & Medium Enterprises (MSME) for the promotion of Ayush enterprises.

Ensure time-bound Infrastructure development of Ayush National Institutes/Central Councils projects: Sonowal

Ministry of Ayush has fast tracked up-gradation and construction of various Ayush Infrastructure across the country

PIB: Pharmaceutical industry in Maharashtra

The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.

PIB: Pharma companies manufacturing generic medicine

Under the PMBJP, till 30.06.2022, 8742 PMBJKs have been opened across the country including Government Hospitals and Government premises.

PIB: India imported Rs. 35,249 crore worth APIs and Bulk drugs in 2021-22.

India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.